IL6 and neoplasm: To examine the clinical relevance of the MUC1-EGFR-IL-6 axis in cancer patients, we collected 20 paired pre- and post-NACT tumor specimens from cervical cancer patients (Supplementary Table S6) and performed immunohistochemistry to detect the expression of MUC1, EGFR, and IL-6.